Zepbound cost in 2026: list price, self-pay, and the $25 copay

“How much does Zepbound cost?” has no single answer, because Zepbound has at least three prices depending on how you get it. The headline number you see in the news — over a thousand dollars a month — is a list price almost no one actually pays. What you pay depends on your insurance, Lilly’s direct programs, and whether you qualify for a savings card. Here is the current map, with figures verified from Lilly’s own pages as of June 2026. For how GLP-1 pricing works in general, see our explainer on GLP-1 cost and insurance coverage.

List price vs what you actually pay

Zepbound’s monthly list price is approximately $1,086 for a 28-day supply, across all pen strengths.^[1] But list price is a sticker, not a bill. Almost everyone pays through one of two doors instead: their insurance (if it covers Zepbound), or Lilly’s own self-pay program for those without coverage. Which door you walk through changes the number by an order of magnitude.

The self-pay tiers (no insurance)

For people paying out of pocket, Lilly’s self-pay program prices single-dose vials by dose, as a 4-week supply: $299/month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg and above(as of June 2026).^[2] There is a catch worth flagging: the $449 price for the higher doses depends on refilling within 45 days of your previous delivery. Miss that window and the price reverts to roughly $499 (7.5 mg) or about $699 (10 mg and up).^[2] The 2.5 mg dose is a starter strength, not a maintenance dose, so most people settle at the $449 tier.

The savings card (if you’re commercially insured)

If you have commercial insurance that covers Zepbound, the manufacturer savings card can bring your copay down to as little as $25 for a 1-, 2-, or 3-month fill.^[2]The fine print matters: savings are capped at $100 per month (up to $300 for a 3-month fill), with a separate annual maximum of $1,300, and a limit of 13 fills per calendar year; the current card expires December 31, 2026.^[2] If your commercial plan does not cover Zepbound, the savings card instead routes you toward a self-pay price (as low as $299 for the starter dose).^[2]

Compounded tirzepatide is no longer a legal discount

During the 2023–24 shortage, compounded tirzepatide was a cheap workaround. That door has largely closed. The FDA declared the tirzepatide shortage resolved in October 2024, which ended the broad compounding exceptions, and in May 2026 the FDA went further, proposing to exclude tirzepatide (along with semaglutide and liraglutide) from the list of bulk substances outsourcing facilities may compound.^[3] The practical takeaway: a cheap “compounded tirzepatide” offer in 2026 is operating in a shrinking and legally contested space, not a settled discount channel.

Why the price is a clinical issue, not just a budgeting one

Cost is not separate from whether the drug works, because tirzepatide only keeps working while you keep taking it. Real-world studies of why people stop GLP-1 and dual-agonist therapy find that cost and loss of coverage are among the leading reasons for discontinuation, alongside side effects.^[4] Since stopping typically reverses much of the weight loss, an affordability gap is effectively a treatment failure. The cheapest plan that you can sustain usually beats a slightly cheaper one you can’t.

The honest bottom line

If you have commercial insurance that covers Zepbound, the savings card likely puts you near $25 a month. If you’re paying cash, Lilly’s self-pay vials run $299–$449 depending on dose, provided you refill on schedule. If you’re on Medicare or Medicaid, the savings programs don’t apply and coverage depends on your plan. Compounded tirzepatide is no longer a reliable or clearly legal discount. Prices in this market change often, so verify the current figure on Lilly’s site before you budget. For how the actual results compare with Wegovy — and whether the price gap is worth it — see Zepbound vs Wegovy, and our guide to GLP-1 providers for the routes to a prescription.